The headline reads as positive (72% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › OPK
Opko Health, Inc. (OPK) stock analysis
WEAK BUY 30% confidence · analysed Oct 15, 2026
On Oct 15, 2026, our model rated Opko Health, Inc. (OPK) WEAK BUY with 30% confidence at a price of $1.59. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$1.59
Trade plan from the model
The model's long / bullish plan uses an entry near $1.59, a target of $1.76 (+10.7%) and a stop-loss at $1.44 (-9.4%).
That is a reward-to-risk ratio of about 1.1 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Oct 25, 2026 whatever the price does.
Entry$1.59
Target$1.76
Stop-loss$1.44
Reassess byOct 25, 2026
The model's one-paragraph read
Leans BUY — composite score +0.30 (WEAK BUY). Technicals: RSI 45.36, MACD bearish, price above SMA50. Fundamentals: PEG 93.65, margin -12.4%, revenue growth 4.3%. Financial results: YoY revenue +4.3%, last EPS surprise +72.7%, next earnings 2026-10-28. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bullish order block, price retesting a bearish order block. FinGPT news read: neutral. Internet research: OPKO’s **bull case** is centered on the expanded FDA indication for its 4Kscore prostate-cancer test, potential diagnostics margin improvement, and a stronger balance sheet after Labcorp agreed to buy selected BioReference assets for $722 million, plus up to $150 million in earnouts. The **bear case** is that OPK remains loss-making, cash-flow negative, and in a technical downtrend, with recent quarterly revenue near $163.6 million versus an $8.4 million net loss. The major recent catalyst is Labcorp’s BioReference transaction, which drove OPK shares roughly 20% higher premarket on October 15, while the 4Kscore expansion added further pipeline and revenue optimism. Analyst sentiment remains mixed, with a consensus Hold rating and average price target of about $1.55. Suggested levels: entry $1.59, target $1.76, stop-loss $1.44, exit by 2026-10-25 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for OPK
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 15, 2026 | WEAK BUY | 30% | $1.59 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on OPK
Oct 15, 2026 · Labcorp outlays up to $872m to acquire BioReferences laboratory assets
- Oct 15, 2026: Labcorp to buy BioReference assets for up to $872M (MedTech Dive)
- Oct 15, 2026: Labcorp outlays up to $872m to acquire BioReferences laboratory assets (Medical Device Network)
- Oct 15, 2026: Opko Health stock soars on $722M BioReference asset sale (Investing.com)
Frequently asked questions
Is OPK a buy right now?
As of Oct 15, 2026, our automated model rates Opko Health, Inc. (OPK) WEAK BUY with 30% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for OPK?
The model's most recent plan targets $1.76 with a stop-loss at $1.44, from an entry near $1.59.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.